Progress in small-molecule inhibitors of Bcl-2 family proteins

Yaoxue Xuebao

Volumn 43, Issue 7, 2008, Pages 669-677

  Tang, Yong ^a   Zhang, Da yong ^a   Wu, Xiao ming ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Bcl 2; Drug design; Inhibitor

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 5 (4 BROMOBENZYLIDENE) ALPHA ISOPROPYL 4 OXO 2 THIOXO 3 THAZOLIDINEACETIC ACID; 5-(4-BROMOBENZYLIDENE)-ALPHA-ISOPROPYL-4-OXO-2-THIOXO-3-THAZOLIDINEACETIC ACID; ABT-737; ANTIMYCIN A1; ANTINEOPLASTIC AGENT; BENZOPYRAN DERIVATIVE; BIPHENYL DERIVATIVE; ETHYL 2-AMINO-6-BROMO-4-(1-CYANO-2-ETHOXY-2-OXOETHYL)-4H-CHROMENE-3-CARBOXYLATE; GOSSYPOL; HERBACEOUS AGENT; NITRILE; NITROPHENOL; PIPERAZINE DERIVATIVE; PROTEIN BCL 2; PROTEIN BCL X; SULFONAMIDE; THIAZOLE DERIVATIVE;

APOPTOSIS; CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFECT; HUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

ANTIMYCIN A; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; BENZOPYRANS; BIPHENYL COMPOUNDS; CELL LINE, TUMOR; DRUG DESIGN; DRUGS, CHINESE HERBAL; GOSSYPOL; HUMANS; NITRILES; NITROPHENOLS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; THIAZOLES;

EID: 50549085284     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Muchmore SW, Sattler M, Liang H, et al. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death [J]. Nature, 1996, 381: 335-341.
2. Petros AM, Olejniczak ET, Fesik SW. Structural biology of the Bcl-2 family of proteins [J]. Biochim Biophys Acta, 2004, 1644:83-94.
3. Liu XJ, Zhang LQ, Liu XL, et al. Role for the Bcl-2 family proteins and BH3 domain in apoptosi [J]. Prog Biochem Biophys, 2006, 33:221-222.
4. Adams JM, Cory S. Bcl-2-regulated apoptosis; mechanism and therapeutic potential [J]. Curr Opin Immunol, 2007, 19:488-496.
5. Degterev A, Lugovskoy A, Cardone M, et al. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL [J]. Nat Cell Biol, 2001, 3:173-182.
6. Xing CG, Wang LY, Tang XH, et al. Development of selective inhibitors for anti-apoptotic Bcl-2 proteins from BHI-1 [J]. Bioorg Med Chem, 2007, 15:2167-2176.
7. Wang LY, Kong FS, Kokoski CL, et al. Development of dimeric modulators for anti-apoptotic Bcl-2 proteins [J]. Bioorg Med Chem Lett, 2008, 18:236-240.
8. Wang JL, Liu DX, Zhang ZJ, et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells [J]. Proc Natl Acad Sci, 2000, 97:7124-7129.
9. Lickliter JD, Wood NJ, Johnson L, et al. HA14-1 selectively induces apoptosis in Bcl-2-overexpressing leukemia/lymphoma cells, and enhances cytarabine-induced cell death [J]. Leukemia, 2003, 17: 2074-2080.
10. Doshi JM, Tian DF, Xing CG. Structure-activity relationship studies of ethyl 2-umino-6-bromo-4-( 1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3- curboxylate (HA14-1), un antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer [J]. J Med Chem, 2006, 49:7731-7739.
11. Doshi JM, Tian DF, Xing CG. Ethyl-2-amino-6-bromo-4-(1-cyano-2-ethoxy-2- oxoethyl)-4H-chromene-3-carboxylate (HA14-1), a prototype small-molecule antagonist against antiapoptotic Bcl-2 proteins, decomposes to generate reactive oxygen species that induce apoptosis [J]. Mol Pharm, 2007, 4:919-928.
12. Tian DF, Das SG, Doshi JM, et al. sHAI4-1, a stable and ROS-free antagonist against anti-apoptotic Bcl-2 proteins, bypasses drug resistances and synergizes cancer therapies in human leukemia cell [J]. Cancer Lett, 2008, 259:198-208.
13. Enyedy IJ, Ling Y, Nacro K, et al. Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening [J]. J Med Chem, 2001, 44:4313-4324.
14. Shuker SB, Hajduk PJ, Meadows RP, et al. Discovering high-affinity ligands for proteins: SAR by NMR [J]. Science, 1996, 274:1531-1535.
15. Petros AM, Dinges J, Augeri DJ, et al. Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis [J]. J Med Chem, 2006, 49:656-663.
16. Park CM, Oie T, Petros AM, et al. Design, synthesis, and computational studies of inhibitors of Bcl-xL [J]. J Am Chem Soc, 2006, 128:16206-16212.
17. Wendt MD, Shen W, Kunzer A, et al. Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo [J]. J Med Chem, 2006, 49: 1165-1181.
18. Bruncko M, Oost TK, Belli BA, et al. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL [J]. J Med Chem, 2007, 50:641-662.
19. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours [J]. Nature, 2005, 435:677-681.
20. Gaizo Moore VD, Brown JR, Certo M, et al. Chronic lymphocytic leukemia requires Bcl-2 to sequester prodeath BIM, explaining sensitivity to Bcl-2 antagonist ABT-737 [J]. J Clin Inves, 2007, 117:112-121.
21. Van Delft M, Wei A, Mason K, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized [J]. Cancer Cell, 2006, 10:389-399.
22. Tuma RS. Novel small molecule promotes programmed cell death; "new drugs on the horizon" session [AACR annual meeting] [J]. Oncol Times, 2007, 29:38-40.
23. Park CM. Discovery of ABT-263, an orally active small molecule inhibitor of anti-apoptotic Bcl-2 family proteins [C]. American Chemical Society Western Regional Meeting, 2007.
24. Wang S, Yang D. Small molecule inhibitor targeted at Bcl-2: CN, 1589135A[P], 2005-03-02.
25. Kitada S, Leone M, Sareth S, et al. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins [J]. J Med Chem, 2006, 46:4259-4264.
26. Wang GP, Nikolovska-Coleska Z, Yang CY, et al. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins [ J]. J Med Chem, 2006, 49:6139-6142.
27. Zeitlin BD, Joo E, Dong ZH, et al. Antiangiogenic effect of TW37, a small-molecule inhibitor of Bcl-2 [J]. Cancer Res, 2006, 66:8698-8706.
28. Tang GZ, Yang CY, Nikolovska-Coleska Z, et al. Pyrogallol-based molecules as potent inhibitors of the antiapoptotic Bcl-2 proteins [J]. J Med Chem, 2007, 50:1723-1726.
29. Tang GZ, Nikolovska-Coleska Z, Qiu S, et al. Acylpyrogallols as inhibitors of antiapoptotic Bcl-2 proteins [J]. J Med Chem, 2008, 51:717-720.
30. Tang GZ, Ding K, Nikolovska-Coleska Z, et al. Structure-based design of flavonoid compounds as a new class of small-molecule inhibitors of the anti-apoptotic Bcl-2 proteins [J]. J Med Chem, 2007, 50:3163-3166.
31. Yin H, Lee GI, Sedey KA, et al. Terphenyl-based Bak BH3 r-helical proteomimetics as low-molecular-weight antagonists of Bcl-xL [J]. J Am Chem Soc, 2005, 27: 10191-10196.
32. Wang Y, Serradell N, Bolos J, et al. Obatoclax mesylate [J]. Drugs Future, 2007, 32:228-233.
33. Tzung SP, Kim KM, Basanez G, et al. Antimycin a mimics a cell-death-inducing Bcl-2 homology domain 3 [J]. Nat Cell Biol, 2001, 3:183-191.
34. Yu ZM, Shah DM. Curcumin down-regulates Ets-1 and Bcl-2 expression in human endometrial carcinoma HEC-1-A cells [J]. Gynecol Oncol, 2007, 106:541-548.
35. Liu YQ, You S, Shinichi T, et al. Oridonin induced U937 cell apoptosis through ERK pathway [J]. China J Chin Mater Med, 2005, 30:1856-1859.
36. Jin LJ, Zhang ZC, Wang YY, et al. A novel small molecule inhibitor targeted at Bcl-2 [J]. Sci China Ser C-Life Sci, 2007, 50:624-629.
37. Zheng CH, Zhou YJ, Zhu J, et al. Construction of a three-dimensional pharmacophore for Bcl-2 inhibitors by flexible docking and the multiple copy simultaneous search method [J]. Bioorg Med Chem, 2007, 15:6407-6417.
38. Pinto M, Perez JJ, Rubio-Martinez J. Molecular dynamics study of peptide segments of the BH3 domain of the proapoptotic proteins Bak, Bax, Bid and Hrk bound to the Bcl-xL and Bcl-2 proteins [J]. J Comput Aided Mol Des, 2004, 18:13-22.